2018, A Year in Review

 In News

We aim to give our members the best possible opportunities to develop, conduct and translate clinical trial research. This year, ALLG achieved an increase in the number and participation of clinical trials, an increase in member engagement, and improved site commitment to the trial program.

Delaine Smith, CEO of ALLG

During 2018, we continued to make gains in our four key strategic directives: to deliver significant scientific outcomes, enhance brand and reputation, foster passionate membership base and ensure long-term sustainability. We have continued to work in alignment to progress our strategic goals by focusing on trial diversity and quality, considering better ways to engage members, and improving our operational efficiency.

Membership reached 799 Members; consisting of 414 Full Members, 335 Associate Members, 43 Community Members and 7 Life Members. We had 22 clinical trials open and were able to develop and approve three new clinical trials during the year. A major focus was on the National Blood Cancer Registry and ways to secure funding for the data registry and sample biobank.

Through our involvement in the Select Committee Inquiry into funding for research into cancers with low survival rates, we were quite pleased with the final report and the 25 recommendations put forward by the committee. The next steps for ALLG will be to remain actively involved in the implementation phase.

Further to this, the ALLG applauded the launch of the landmark report called ‘Economic evaluation of investigator-initiated clinical trials conducted by networks.’ Released in August 2017, by the Australian Commission on Safety and Quality in Health Care and the Australian Clinical Trials Alliance (ACTA), the welcomed report analysed 25 Australian clinical trials initiated by clinicians. One of the most significant findings was the 5.8:1 benefit-to-cost ratio of clinical trials — meaning that for each $1 invested in clinician-driven clinical trials in Australia, benefits of $5.80 can be realised.

ALLG continued efforts with those that share our vision by joining with HSANZ to facilitate the second annual Blood Cancer Forum. Chaired by Prof Andrew Roberts, the forum is an opportunity for the blood cancer foundations and organisations to share common areas for advancing blood cancer initiatives. The forum included representatives from Leukaemia Foundation Australia, Lymphoma Australia, Myeloma Australia, and Snowdome. Three priority areas were identified in 2017, these include improving care for rural, regional and remote communities; access to new medicines; and support for research. The forum explored different ways to action these priority areas as we continue to work in this area.

Through the establishment of a stable structure and financial base, we were able to increase our organisational expertise by employing a Communications & Marketing Manager as well as a Philanthropic & Fundraising Manger to increase brand awareness and long-term sustainability. As a result, the ALLG was able to develop a sound Corporate Communication Strategy and a Philanthropic Strategy.

During the development phase of Corporate Communication Strategy, we identified the need to define our organisational values. Organisational values are necessary to support the vision, shape the culture and reflect the type of organisation the ALLG is by defining the way we work as an organisation with members, staff, stakeholders, and industry partners. Through consultations with the Board, staff, and membership, we identified and adopted four organisational values: integrity, quality, collaboration and innovation.

Thank you to all the members and staff of the ALLG that continue to make ALLG the success it is known for, and we look forward in 2019 to take the ALLG’s scientific endeavours to a new level of achievement and prominence in the world of Haematology and blood cancers.

ALLG Members

Clinical Trial Staff